17,261 trials
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
Urothelial Carcinoma · Urothelial Cancer · Lung Neoplasms
Primary: Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of EP0057 (CLRX101) in Participants With Refractory Cancers. — 12 mg/m^2
Respiratory Syncytial Virus (RSV)
Primary: Part 1: Concentrations of EDP-938 in Plasma — 1132.222; 1989.500; 1819.286; 1420.000 ng/mL
Diffuse Large B-cell Lymphoma
Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants
Prostate Cancer · Vitamin D Deficiency · Stress Reaction
Primary: Percentage of Participants With Change in Transcriptional Profiles After Vitamin D Supplementation. — 100 percentage of subjects
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia/Lymphoma
Primary: Probability of Acute Graft Versus Host Disease (GVHD) — 0; 30 Percent of participants
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
NASH - Nonalcoholic Steatohepatitis
Primary: Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis — 0.24; 0.25; 0.27; 0.23 score on a…
Solid Tumor, Adult
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Sleep Initiation and Maintenance Disorders
Primary: Treatment Period: Change From Baseline in Latency to Persistent Sleep (LPS) on Day 30 of Lemborexant 5 mg Compared to Placebo — -46.12; -50.90 minutes — p=0.0133
Tinea Versicolor
Primary: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia (Fungal Cause of Tinea Versicolor) — 2; 4; 5; 1 Participants — p=0.2
Neoplasms
Primary: Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4) — 6; 9; 8; 0 Participants
Malaria,Falciparum
Primary: Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification. — 17; 6; 4 Participants